As a GI focused US healthcare company, collaboration is a core value and a key to our success
US
LINZESS®* available in U.S. through 50/50 collaboration with Allergan
Europe, Canada, Mexico
CONSTELLA® available in certain European countries through partnership with Allergan
China, Hong Kong & Macau
LINZESS® approved in Hong Kong, and in China through a collaboration with AstraZeneca
Japan
LINZESS® available in Japan through partnership with Astellas
Rest of World
License to develop and market linaclotide in remaining countries with Allergan
At Ironwood, we’re focused on three goals: transforming knowledge into medicines that make a difference for people living with gastrointestinal (GI) diseases, building a team that relentlessly pursues excellence and creating value that will inspire the continued support of our fellow shareholders.
These are not easy tasks, and we recognize the value of collaboration in achieving them. Only by working together can we make medicines that make a difference in people’s lives.
Ironwood’s goal is to get our medicines to appropriate patients around the world in the most efficient way possible. We have a track record of establishing, operating and evolving high-performance partnerships globally. With our first internally-developed medicine, linaclotide, we’ve established a network of partners that can help us reach patients.
We collaborate with the major GI physician and patient advocacy groups to support research and understanding with the aim to advance medicines and improve patient care.
As a GI focused, US healthcare company, we are interested in discussing opportunities to collaborate on GI products. We are also seeking partners in territories outside of the US for select current development programs. Please contact us with more details on your area of interest.
Partner with UsCopyright © 2019, Ironwood Pharmaceuticals, Inc. All Rights Reserved
LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.